Wells Fargo analyst Stephen Baxter raised the firm’s price target on Elevance Health (ELV) to $412 from $330 and keeps an Overweight rating on the shares. The firm is updating estimates and price targets in the space ahead of Q3 2025 results. Notability, Wells now assumes extension of enhanced subsidies is likely.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer
- Health Insurance subsidies central to government shutdown negotiation, WSJ says
- Trump says working on reducing cost of health insurance
- Elevance Health Issues New Series of Notes